The PARP inhibitor Olaparib disrupts base excision repair of 5-aza-2′-deoxycytidine lesions

The PARP inhibitor Olaparib disrupts base excision repair of 5-aza-2′-deoxycytidine lesions

Decitabine (5-aza-2′-deoxycytidine, 5-azadC) is used in the treatment of Myelodysplatic syndrome (MDS) and Acute Myeloid Leukemia (AML). Its mechanism of action is thought to involve reactivation of genes implicated in differentiation and transformation, as well as induction of DNA damage by trappin...

Full description

Bibliographic Details
Main Authors:	Orta, Manuel Luis, Höglund, Andreas, Calderón-Montaño, José Manuel, Domínguez, Inmaculada, Burgos-Morón, Estefanía, Visnes, Torkild, Pastor, Nuria, Ström, Cecilia, López-lázaro, Miguel, Helleday, Thomas
Format:	Online
Language:	English
Published:	Oxford University Press 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4132747/

Similar Items

5-Aza-2′-deoxycytidine causes replication lesions that require Fanconi anemia-dependent homologous recombination for repair
by: Orta, Manuel Luís, et al.
Published: (2013)

Evaluating the Cancer Therapeutic Potential of Cardiac Glycosides
by: Calderón-Montaño, José Manuel, et al.
Published: (2014)

Cells Deficient in the Fanconi Anemia Protein FANCD2 are Hypersensitive to the Cytotoxicity and DNA Damage Induced by Coffee and Caffeic Acid
by: Burgos-Morón, Estefanía, et al.
Published: (2016)

Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate
by: Ström, Cecilia E., et al.
Published: (2011)

OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer
by: Soupos Nikolaos, et al.
Published: (2015-09-01)

The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma
by: Hye Jeong Park, et al.
Published: (2018-05-01)

Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib
by: Nonnekens, Julie, et al.
Published: (2016)

An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma
by: Nile, Donna L., et al.
Published: (2016)

The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
by: Ordóñez, José Luis, et al.
Published: (2015)

5-Aza-2′-deoxycytidine stress response and apoptosis in prostate cancer
by: Patra, Aditi, et al.
Published: (2011)

5-Aza-2′-deoxycytidine-induced genome rearrangements are mediated by DNMT1
by: Maslov, Alexander Y., et al.
Published: (2012)

AID downregulation is a novel function of the DNMT inhibitor 5-aza-deoxycytidine
by: Tsai, Chiou-Tsun, et al.
Published: (2013)

The antileukaemic activity of 5-Aza-2 deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia.
by: Richel, D. J., et al.
Published: (1991)

Comment on ‘Quiescence and γH2AX in neuroblastoma are regulated by Ouabain/Na,K-ATPase': ouabain and cancer
by: Calderón-Montaño, J M, et al.
Published: (2013)

Strategies for the Use of Poly(adenosine diphosphate ribose) Polymerase (PARP) Inhibitors in Cancer Therapy
by: Ström, Cecilia E., et al.
Published: (2012)

Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib
by: Daemen, Anneleen, et al.
Published: (2012)

A Genetic Screen Using the PiggyBac Transposon in Haploid Cells Identifies Parp1 as a Mediator of Olaparib Toxicity
by: Pettitt, Stephen J., et al.
Published: (2013)

Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells
by: Miyasaka, Aki, et al.
Published: (2014)

PARP inhibition by olaparib or gene knockout blocks asthma-like manifestation in mice by modulating CD4+ T cell function
by: Ghonim, Mohamed A, et al.
Published: (2015)

PARP is activated in human asthma and its inhibition by olaparib blocks house dust mite-induced disease in mice
by: Ghonim, Mohamed A., et al.
Published: (2015)

JF-305, a pancreatic cancer cell line is highly sensitive to the PARP inhibitor olaparib
by: YANG, XUELI, et al.
Published: (2015)

Poly(ADP-Ribose) Polymerase 1 (PARP1) Overexpression in Human Breast Cancer Stem Cells and Resistance to Olaparib
by: Gilabert, Marine, et al.
Published: (2014)

Olaparib in the management of ovarian cancer
by: Bixel, Kristin, et al.
Published: (2015)

Comparison of the antileukaemic activity of 5 aza-2-deoxycytidine and arabinofuranosyl-cytosine in rats with myelocytic leukaemia.
by: Richel, D. J., et al.
Published: (1988)

FOXO3/FKHRL1 is activated by 5-aza-2-deoxycytidine and induces silenced caspase-8 in neuroblastoma
by: Geiger, Kathrin, et al.
Published: (2012)

5-Azacytidine and 5-aza-2'-deoxycytidine behave as different antineoplastic agents in B16 melanoma.
by: Cortvrindt, R., et al.
Published: (1987)

GSTP1 DNA Methylation and Expression Status Is Indicative of 5-aza-2′-Deoxycytidine Efficacy in Human Prostate Cancer Cells
by: Chiam, Karen, et al.
Published: (2011)

The epigenetic modifiers 5-aza-2'-deoxycytidine and trichostatin A influence adipocyte differentiation in human mesenchymal stem cells
by: Zych, J., et al.
Published: (2013)

Epigenetic Therapy of Non-Small Cell Lung Cancer Using Decitabine (5-Aza-2′-Deoxycytidine)
by: Momparler, Richard L.
Published: (2013)

Effects of 5-Aza-2′-deoxycytidine on the methylation state and function of the WWOX gene in the HO-8910 ovarian cancer cell line
by: YAN, HONGCHAO, et al.
Published: (2013)

Pharmacokinetic and pharmacodynamic analysis of 5-aza-2’-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy
by: Karahoca, Metin, et al.
Published: (2013)

5-Aza-2′-deoxycytidine Leads to Reduced Embryo Implantation and Reduced Expression of DNA Methyltransferases and Essential Endometrial Genes
by: Ding, Yu-Bin, et al.
Published: (2012)

Gene expression profiling of the synergy of 5-aza-2′-deoxycytidine and paclitaxel against renal cell carcinoma
by: Han, Tiandong, et al.
Published: (2012)

Antineoplastic activity of the DNA methyltransferase inhibitor 5-aza-2′-deoxycytidine in anaplastic large cell lymphoma
by: Hassler, Melanie R., et al.
Published: (2012)

Anticancer efficacy of cisplatin and trichostatin A or 5-aza-2′-deoxycytidine on ovarian cancer
by: Meng, F, et al.
Published: (2013)

Aza-deoxycytidine induces apoptosis or differentiation via DNMT3B and targets embryonal carcinoma cells but not their differentiated derivatives
by: Wongtrakoongate, P, et al.
Published: (2014)

Treating Cloned Embryos, But Not Donor Cells, with 5-aza-2’-deoxycytidine Enhances the Developmental Competence of Porcine Cloned Embryos
by: HUAN, Yan Jun, et al.
Published: (2013)

Synergistic and antagonistic AML cell type-specific responses to 5-AZA-2’-Deoxycytidine and 1-H-D-Arabinofuranosylcytosine
by: Elmoneim, Abeer Abd, et al.
Published: (2014)

A Perspective on the Comparative Antileukemic Activity of 5-Aza-2′-deoxycytidine (Decitabine) and 5-Azacytidine (Vidaza)
by: Momparler, Richard L.
Published: (2012)

Delineating the effect of demethylating agent 5-aza-2′-deoxycytidine on human Caco-2 colonic carcinoma cells
by: LI, XIUMEI, et al.
Published: (2016)